LUNG241018C7500
- 0.85
- 0.000.00%
Pulmonx Newsroom
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
Wells Fargo Reaffirms Their Hold Rating on Pulmonx (LUNG)
Wells Fargo Maintains Pulmonx(LUNG.US) With Hold Rating, Maintains Target Price $10
Aeriseal's Market Potential and Safety Profile: Justifying a Hold Rating for Pulmonx
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
Pulmonx (LUNG) Gets a Buy From Lake Street
CCORF Maintains Pulmonx(LUNG.US) With Buy Rating, Raises Target Price to $16
Buy Rating Affirmed for Pulmonx: Strong Growth and Promising Clinical Advancements
Pulmonx Price Target Cut to $10.00/Share From $14.00 by Wells Fargo
Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $10
Pulmonx Analyst Ratings
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains Pulmonx(LUNG.US) With Buy Rating, Raises Target Price to $16
Wells Fargo Maintains Pulmonx(LUNG.US) With Hold Rating, Cuts Target Price to $10
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $12
Lake Street Remains a Buy on Pulmonx (LUNG)
Pulmonx Analyst Ratings
Canadian Investment Banking Group: Maintaining the Pulmonx (LUNG.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $16.00 to $15.00.